Schering-Plough/Merck File Claritin, Singulair Combination
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA has been accepted by FDA for a standard 10-month review.
You may also be interested in...
Schering-Plough’s Cholesterol Franchise Holds 16.4 Percent Of New Scripts
Sales of Vytorin and Zetia climb 48 percent to $1.2 billion during the first quarter.
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: